Moderna stock forfeits gains as first US bird flu death puts vaccine development in focus
Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.
Moderna stock on track for 20% weekly gain after US bird flu death
Moderna stock was on track to see a weekly gain of over 20% as of Wednesday following the first reported bird flu death in the US.
Moderna stock seesaws as first US bird flu death puts vaccine development in focus
Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...
GSK, Pfizer RSV shots must warn about rare paralysis risk
Barré for every million doses given.
Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference
Curevo’s CEO, George Simeon, will discuss updated data from Curevo’s 876-patient head-to-head trial of amezosvatein, a non-mRNA adjuvanted subunit vaccine for shingles, versus Shingrix ®.
New Buy Rating for Wheaton Precious Metals (WPM), the Basic Materials Giant
Berenberg Bank analyst Kerry Holford maintained a Buy rating on Wheaton Precious Metals (WPM – Research Report) yesterday and set a price ...
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Glucagon-Like Peptide-1 Analogs Market Projected To Witness Substantial Growth, 2025-2032: Sanofi, Astrazeneca Plc
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.
Hosted on MSN7h
High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination
A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...
Wayne biotech firm received $67.5 million investment to test gene therapy for heart disease
XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...